What Are GLP-1 Drugs and Why Are They Changing Diabetes Care?
GLP-1 (glucagon-like peptide-1) is a hormone released by the intestines after eating. In the body, it performs several critical functions: it stimulates insulin secretion from the pancreas in a glucose-dependent manner (meaning it only releases insulin when glucose is actually elevated — dramatically reducing hypoglycaemia risk), suppresses glucagon (the hormone that raises blood sugar between meals), slows gastric emptying (reducing the rate at which glucose enters the bloodstream after eating), and — perhaps most importantly for obesity — signals the hypothalamus in the brain to reduce hunger and increase satiety.
GLP-1 receptor agonists are drugs that mimic and amplify this natural hormone. The result is a multi-pronged effect: better blood sugar control, significant weight loss, and — as large cardiovascular outcome trials have established — profound reduction in heart attack and kidney disease risk. This is the genuinely new part. Prior generations of diabetes drugs lowered blood sugar. GLP-1 drugs lower blood sugar and reduce cardiovascular death rates.
The clinical trial evidence base is now extremely robust:
- The LEADER trial (liraglutide) and SUSTAIN-6 trial (semaglutide) established 26% and 26% reductions respectively in major cardiovascular events in type 2 diabetics.
- The SELECT trial (semaglutide 2.4mg / Wegovy) extended this cardiovascular benefit to non-diabetic obese patients — a paradigm shift confirming that obesity itself, not just diabetes, drives cardiovascular risk that GLP-1 drugs can modify.
- The SURMOUNT-1 trial (tirzepatide / Mounjaro) demonstrated up to 22.5% body weight reduction — the largest weight loss ever recorded for a pharmaceutical agent in a clinical trial.
In India, the stakes are particularly high. With 77 million people living with type 2 diabetes — the second largest diabetic population in the world — and over 300 million people classified as overweight or obese, GLP-1 drugs have extraordinary public health relevance. Dr. Anil Bhansali, who was involved in the Indian introduction of several of these agents and has treated over 1,200 patients on GLP-1 therapy at Gini Advanced Care Hospital, brings both trial expertise and hard-won real-world clinical experience to this comparison.
Dr. Bhansali's team assesses every patient individually — HbA1c, BMI, cardiovascular risk, and goals — before recommending any agent.
Mounjaro (Tirzepatide) — The Dual-Action Advantage
Mounjaro is not just another GLP-1 drug — it is a fundamentally different mechanism. While Ozempic and Wegovy activate only GLP-1 receptors, Mounjaro is a dual agonist that activates both GLP-1 receptors AND GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. GIP is a second incretin hormone that amplifies the metabolic effects of GLP-1 — particularly for weight loss and fat tissue remodelling.
The clinical consequences of this dual action are meaningful:
- SURPASS trial programme (6 trials, 40,000+ patients): HbA1c reduction of 2.1–2.3 percentage points at maximum dose. To contextualise: a 2.0% HbA1c reduction is extraordinarily difficult to achieve with any single oral agent. Achieving this with a weekly injection represents a step change in diabetes management.
- SURMOUNT-1 trial (obesity without diabetes): 22.5% mean body weight reduction at 15mg/week over 72 weeks. At the highest dose, some participants lost over 25% of their body weight — comparable to bariatric surgery outcomes in clinical trials for the first time.
- SURPASS-2 head-to-head vs Ozempic 1mg: Mounjaro at 10mg and 15mg outperformed semaglutide 1mg on both HbA1c (by 0.5 percentage points) and weight loss (by approximately 5kg). This is the most clinically relevant direct comparison available.
Who Mounjaro is ideal for: Type 2 diabetes with HbA1c above 8.0% who want maximum glucose AND weight effect simultaneously. Obesity-associated type 2 diabetes where weight loss is the primary therapeutic driver. Patients who have failed to achieve target HbA1c on semaglutide or other GLP-1 agents.
Dosing in India: Available in 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg weekly subcutaneous injection pens. Titration typically over 4–5 months from 2.5mg to effective dose. Dr. Bhansali's team does not rush titration — reaching the effective dose, not the maximum dose, is the goal.
Wegovy vs Ozempic — Same Drug, Different Doses, Different Goals
Ozempic and Wegovy contain exactly the same molecule — semaglutide. The critical difference is dose and approved indication, which reflects different therapeutic goals:
Ozempic (semaglutide 0.5mg → 1mg → 2mg): Licensed and approved specifically for type 2 diabetes management. Also produces significant weight loss as a beneficial secondary effect — 8–12% at 1mg dose. The SUSTAIN and PIONEER trial programmes established exceptional HbA1c reduction (~1.5 percentage points). The SELECT cardiovascular outcome trial confirmed cardiovascular and kidney-protective benefits in diabetic patients. Ozempic 2mg was approved in India in 2023 and has the widest market availability and the longest safety record in the Indian market.
Wegovy (semaglutide 2.4mg): The same molecule at a higher dose, specifically developed and approved for obesity management in patients with BMI ≥30, or ≥27 with obesity-related comorbidities (hypertension, dyslipidaemia, sleep apnoea, cardiovascular disease). The STEP trial programme (5 trials) demonstrated 14–17% body weight reduction — substantially more than Ozempic 1mg, reflecting the dose-response relationship. The SELECT trial further confirmed cardiovascular benefit in non-diabetic obese patients — a first for a weight management drug.
The decision framework:
- Primary goal is diabetes management → Ozempic or Mounjaro
- Primary goal is obesity management (BMI ≥30), may or may not have diabetes → Wegovy or Mounjaro
- Both high HbA1c AND significant obesity (BMI ≥30 with HbA1c ≥8.0%) → Mounjaro is the strongest evidence-based option
- Cost is a significant constraint → Ozempic remains the most accessible and cost-effective entry point
| Ozempic | Wegovy | Mounjaro | |
|---|---|---|---|
| Molecule | Semaglutide 1mg | Semaglutide 2.4mg | Tirzepatide |
| Mechanism | GLP-1 agonist | GLP-1 agonist | Dual GLP-1 + GIP |
| HbA1c Reduction | ~1.5% | ~1.3% | ~2.1–2.3% |
| Weight Loss (trials) | 8–12% | 14–17% | 15–22% |
| Primary Use | Type 2 Diabetes | Obesity | Diabetes + Obesity |
| CV Outcome Data | Yes (SUSTAIN-6) | Yes (SELECT) | In progress (SURPASS-CVOT) |
| India Cost/Month | ₹4,000–8,000 | ₹12,000–20,000 | ₹7,000–18,000 |
| India Availability | Wide | Import-dependent | Expanding |
Side Effects — What 1,200 Gini Patients Have Actually Experienced
Clinical trial side effect data is essential but not sufficient. Real-world clinical practice reveals practical patterns that trials, with their highly selected populations and intensive monitoring, often understate. Dr. Bhansali's team has managed over 1,200 patients on GLP-1 therapy — here is what they have actually observed and how they manage it.
Nausea (30–40% of patients)
Nausea is the most common side effect and is worst in weeks 1–4 of therapy, particularly at dose escalation points. It reflects the drug's mechanism of slowing gastric emptying — the stomach is literally emptying more slowly than the patient is accustomed to. Practical management from Dr. Bhansali's practice: eat smaller meals (4–5 small meals rather than 2–3 large ones), avoid high-fat or spicy food for the first 4–6 weeks, take the injection at night so peak drug levels occur during sleep, and pace dose escalation. Most patients adapt after 4–6 weeks at each dose level.
Constipation (20–30% of patients)
Significantly underreported in clinical trials. The same mechanism that slows gastric emptying (therapeutic for diabetes) slows intestinal transit. Practical management: increase water intake to 3+ litres per day, increase dietary fibre (fruits, vegetables, whole grains), and consider a mild osmotic laxative during the titration phase. This almost always resolves once the dose stabilises.
Reduced appetite (15–25% — this is the mechanism, not a complication)
Reduced appetite is the primary therapeutic driver for weight loss. However, some patients dramatically undereat, which risks muscle loss, micronutrient deficiency, and fatigue. Dr. Bhansali's team monitors protein intake carefully — minimum 1.2g of protein per kilogram of body weight per day is non-negotiable on GLP-1 therapy. Patients are provided with structured dietary guidance at initiation, not left to manage this alone.
Vomiting (5–10% of patients)
Almost always caused by excessive dose escalation speed. Patients who rush to maximum dose in 6 weeks instead of 20 weeks experience significantly higher rates of vomiting. Solution: unhurried titration. There is no prize for speed.
Pancreatitis (rare — <2%)
GLP-1 drugs carry a class warning for pancreatitis. Dr. Bhansali's team screens all patients for history of pancreatitis, gallstones (a risk factor for pancreatitis), or hypertriglyceridaemia before initiating therapy. Patients with a clear history of pancreatitis are not candidates for GLP-1 therapy without careful individual risk-benefit assessment.
"The patients who struggle most are those who rush the dose escalation. We always tell patients: there is no prize for reaching maximum dose fastest. Your job is to reach the dose that works for you — which may be 5mg Mounjaro, not 15mg. Do not chase the trial dose."
Cost and Availability in India — What You Need to Know in 2026
The Indian GLP-1 market has evolved significantly since 2022. Here is the current landscape as of April 2026:
Ozempic (Semaglutide) — Most Accessible
Ozempic is widely available across Indian pharmacies and hospital formularies. Generic versions of oral semaglutide (Rybelsus, available in 3mg, 7mg, and 14mg tablets) offer a lower-cost oral alternative — bioavailability is approximately 1% (vs subcutaneous injection), so the dose and monitoring requirements differ, but for cost-sensitive patients who cannot tolerate injections, it is an effective option. Monthly cost for Ozempic injection: ₹4,000–8,000 depending on dose. Rybelsus oral: ₹2,500–5,000/month.
Mounjaro (Tirzepatide) — Expanding
Available in India since 2024, initially through import channels, with local manufacturing partnerships expected to expand supply and reduce cost through 2026. Now available in major Indian cities through specialist prescriptions. Monthly cost: ₹7,000–18,000 depending on dose. At the 5mg and 7.5mg doses most patients stabilise at, real-world cost is typically ₹8,000–12,000/month. Some corporate insurance policies are beginning to cover Mounjaro for diabetes indications — check with your insurer.
Wegovy (Semaglutide 2.4mg) — Available but Import-Dependent
Wegovy is available in India but supply is import-dependent and less consistent than Ozempic. Monthly cost: ₹12,000–20,000 — the highest cost option in this comparison. Insurance coverage for Wegovy (obesity without diabetes) remains very limited in Indian policies as of 2026. Patients seeking Wegovy for obesity management without diabetes should discuss cost sustainability at initiation — starting a drug they cannot afford to maintain long-term is counterproductive.
GLP-1 drugs purchased online without medical supervision — from grey market sources, unregulated import agents, or social media sellers — carry serious risks: counterfeit products with incorrect active ingredient, wrong dosing, no monitoring of side effects or efficacy, and no assessment of contraindications. Always obtain GLP-1 drugs through a licensed pharmacy under specialist prescription. Call 0172 4120100 to discuss supervised initiation at Gini.
Who Should NOT Use GLP-1 Therapy
GLP-1 therapy is not appropriate for everyone. A thorough pre-prescribing assessment is mandatory. Here are the absolute contraindications and relative cautions that Dr. Bhansali's team screens for at every initiation:
Absolute Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC). GLP-1 receptors are expressed in thyroid C cells. Animal studies showed dose-dependent thyroid C-cell tumours. Human data does not confirm this risk, but MTC history or family history of MEN2 syndrome is an absolute contraindication for all GLP-1 drugs.
- Multiple Endocrine Neoplasia type 2 (MEN2) syndrome. MEN2 is genetically linked to medullary thyroid cancer. GLP-1 drugs are absolutely contraindicated.
- Pregnancy. GLP-1 therapy must be stopped a minimum of 2 months before planned conception. The drugs should not be used during pregnancy or breastfeeding. Women of reproductive age on GLP-1 therapy should use reliable contraception and discuss pregnancy planning with their endocrinologist.
- Severe gastroparesis. GLP-1 drugs slow gastric emptying further. In patients with established gastroparesis — a common complication of long-standing diabetes — this can cause severe nausea, vomiting, and aspiration risk. Gastroparesis must be assessed and managed before any GLP-1 initiation.
Relative Cautions — Individual Assessment Required
- History of pancreatitis. GLP-1 drugs carry a class warning. Dr. Bhansali's team assesses each case: remote history of a single episode with a clear precipitant (gallstones, alcohol) that has been resolved may be manageable with careful monitoring. Recurrent or idiopathic pancreatitis is a stronger relative contraindication.
- Active gallstone disease. GLP-1 drugs reduce gallbladder contractility and slightly increase gallstone risk. Active symptomatic gallstones should be treated before GLP-1 initiation.
- Severe renal impairment (GFR below 15). Dose adjustment and enhanced monitoring for renal function are required. GLP-1 drugs can cause volume depletion through nausea-related reduced intake.
- Eating disorders (restrictive). The appetite-suppressing effect of GLP-1 drugs may worsen anorexia nervosa or restrictive eating patterns. Psychological assessment is recommended before initiation in patients with known or suspected eating disorders.
Who May Not Benefit
Patients with normal BMI (below 25) and normal or near-normal HbA1c seeking weight loss for cosmetic reasons are unlikely to achieve significant results and are not appropriate candidates. Type 1 diabetes — GLP-1 drugs are not the primary mechanism for Type 1, which requires insulin. They can sometimes be used as adjuncts under endocrinologist guidance to reduce insulin dose and improve weight, but this is a specialist decision in each case.
Frequently Asked Questions
Yes — Mounjaro (tirzepatide) has been available in India since 2024. Availability has expanded significantly through 2025–2026 as both import supply and local distribution have improved. Dr. Bhansali's team at Gini can prescribe and monitor it as part of a comprehensive diabetes or obesity management programme.
Call 0172 4120100 for current availability, pricing, and to discuss whether Mounjaro is appropriate for your situation.
Clinical trial data and real-world experience differ — here is both:
- Mounjaro: 15–22% body weight in trials over 72 weeks. Real-world in Dr. Bhansali's practice: typically 8–15% in the first 6 months.
- Wegovy: 14–17% in trials. Real-world: typically 10–14% over 6 months.
- Ozempic: 8–12% in trials. Real-world: typically 6–10% over 6 months.
Results are maximised when combined with structured dietary guidance and resistance training — GLP-1 drugs are powerful tools, not standalone solutions. Patients who work with a dietitian and exercise programme alongside the medication consistently outperform those who take the drug alone.
Yes — if you have obesity (BMI ≥30) with related conditions such as hypertension, sleep apnoea, dyslipidaemia, PCOS, or pre-diabetes, GLP-1 therapy is clinically indicated. The SELECT trial (Wegovy) and SURMOUNT programme (Mounjaro) have established efficacy and safety specifically in patients without type 2 diabetes.
Wegovy is the formally approved obesity agent. Mounjaro's obesity indication (marketed as Zepbound in several markets) is being approved in multiple countries. Dr. Bhansali assesses each patient individually — BMI, metabolic risk factors, and treatment goals all inform the decision.
Semaglutide (Ozempic/Wegovy) has over 10 years of safety data from large cardiovascular outcome trials and post-marketing surveillance. Mounjaro has 5+ years of trial data from the SURPASS programme. No serious long-term safety signals have emerged in well-monitored populations.
Annual monitoring recommended for all long-term GLP-1 patients at Gini: thyroid function (particularly in patients with baseline thyroid nodules), serum lipase (pancreatitis screening), renal function, and body composition assessment. The cardiovascular benefit established in the LEADER, SUSTAIN-6, and SELECT trials makes the benefit-risk profile strongly positive for most appropriate patients.
Weight loss from any cause — dietary restriction, bariatric surgery, or medication — inevitably includes some lean mass loss. On GLP-1 drugs, approximately 25–35% of total weight lost may be lean mass, though this varies significantly based on protein intake and exercise.
Mitigation strategy used at Gini:
- Minimum 1.2–1.6g protein per kilogram of body weight per day (enforced dietary guidance at initiation)
- Resistance training 3 times per week minimum (referred to physiotherapy or gym programme)
- Not losing weight too rapidly — target 0.5–1kg per week, not faster
- Body composition monitoring by DEXA or bioimpedance analysis every 6 months for long-term patients
Most of the weight returns within 1–2 years of stopping — this is consistently documented in the STEP 4 extension trial and real-world data. This is not a drug failure — it reflects the biological reality that obesity is a chronic, relapsing disease with a strong neurobiological component. When the drug that reduces hunger signals is removed, the brain's hunger drive returns to its previous set point.
Dr. Bhansali's position: GLP-1 therapy for obesity is a long-term commitment, not a short-course treatment. If cost prevents continuation at the current dose, options include transitioning to oral semaglutide (Rybelsus — lower cost), stepping down to a lower maintenance dose, or exploring insurance coverage. Stopping suddenly without a transition plan leads to rapid weight regain.